
## Loredana Puca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2823497/publications.pdf Version: 2024-02-01



Ι οφερλικά Ριιζλ

#	Article	IF	CITATIONS
1	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 2016, 22, 298-305.	30.7	1,193
2	Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine. Cancer Discovery, 2017, 7, 462-477.	9.4	735
3	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell, 2016, 30, 563-577.	16.8	394
4	Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 2018, 9, 2404.	12.8	246
5	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research, 2019, 25, 43-51.	7.0	177
6	Emerging Variants of Castration-Resistant Prostate Cancer. Current Oncology Reports, 2017, 19, 32.	4.0	150
7	ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications, 2019, 10, 278.	12.8	143
8	N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. Journal of Clinical Investigation, 2019, 129, 3924-3940.	8.2	115
9	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine, 2019, 11, .	12.4	105
10	Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030593.	6.2	76
11	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nature Communications, 2020, 11, 5549.	12.8	76
12	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science, 2022, 376, .	12.6	75
13	α-arrestin 1 (ARRDC1) and β-arrestins cooperate to mediate Notch degradation in mammals. Journal of Cell Science, 2013, 126, 4457-4468.	2.0	52
14	α-Arrestins – new players in Notch and GPCR signaling pathways in mammals. Journal of Cell Science, 2014, 127, 1359-1367.	2.0	50
15	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular Cancer Therapeutics, 2020, 19, 1157-1164.	4.1	44
16	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	24
17	Extracellular Matrix in Synthetic Hydrogelâ€Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Advanced Materials, 2022, 34, e2100096.	21.0	24
18	An emerging role for cytopathology in precision oncology. Cancer Cytopathology, 2016, 124, 167-173.	2.4	23

Loredana Puca

#	Article	IF	CITATIONS
19	Akt Regulates Drug-Induced Cell Death through Bcl-w Downregulation. PLoS ONE, 2008, 3, e4070.	2.5	20
20	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications, 2021, 12, 6377.	12.8	16
21	Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC) Journal of Clinical Oncology, 2017, 35, 5029-5029.	1.6	5
22	Defining a molecular subclass of treatment resistant prostate cancer Journal of Clinical Oncology, 2015, 33, 5004-5004.	1.6	3
23	First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer Journal of Clinical Oncology, 2019, 37, 260-260.	1.6	3
24	Abstract 992: Patient-derived tumor organoids of neuroendocrine prostate cancer. , 2017, , .		1
25	SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT) Journal of Clinical Oncology, 2019, 37, 5065-5065.	1.6	0
26	Extracellular Matrix in Synthetic Hydrogelâ€Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (Adv. Mater. 2/2022). Advanced Materials, 2022, 34, .	21.0	0